PMID- 28800130
OWN - NLM
STAT- MEDLINE
DCOM- 20180725
LR  - 20220330
IS  - 1476-5403 (Electronic)
IS  - 1350-9047 (Print)
IS  - 1350-9047 (Linking)
VI  - 24
IP  - 12
DP  - 2017 Dec
TI  - miR-130a upregulates mTOR pathway by targeting TSC1 and is transactivated by 
      NF-kappaB in high-grade serous ovarian carcinoma.
PG  - 2089-2100
LID - 10.1038/cdd.2017.129 [doi]
AB  - Activation of mammalian target of rapamycin (mTOR) signaling pathway is 
      associated with poor prognosis of epithelial ovarian cancer. The TSC1-TSC2 
      complex is a critical negative regulator of mTOR signaling. Here, we demonstrated 
      that TSC1 was frequently downregulated in high-grade serous ovarian carcinoma 
      (HGSOC) and low TSC1 expression level is associated with advanced tumor stage. We 
      next identified miR-130a to be a negative regulator of TSC1 by targeting its 
      3'UTR. miR-130a was overexpressed in HGSOC and could drive proliferation and 
      invasion/metastasis of ovarian cancer cells. miR-130a could also attenuate 
      rapamycin/starvation-induced autophagy. Ectopic TSC1 expression could block the 
      effects of miR-130a on cell proliferation, migration and autophagy. Finally, we 
      found that miR-130a expression could be upregulated by inflammatory factors and 
      was transactivated by NF-kappaB. Therefore, our findings establish a crosstalk 
      between inflammation and mTOR signaling that is mediated by miR-130a, which might 
      have a pivotal role in the initiation and progression of HGSOC.
FAU - Wang, Yuqiong
AU  - Wang Y
AD  - Department of Cell Biology, Shandong University School of Medicine, Jinan 250012, 
      China.
AD  - Department of Obstetrics and Gynecology, Qilu Hospital, Shandong University, 
      Jinan 250012, China.
FAU - Zhang, Xiyu
AU  - Zhang X
AD  - Department of Molecular Medicine and Genetics, Shandong University School of 
      Medicine, Jinan 250012, China.
FAU - Tang, Wei
AU  - Tang W
AD  - Department of Pathogenic Biology, Shandong University School of Medicine, Jinan 
      250012, China.
FAU - Lin, Zhenghong
AU  - Lin Z
AD  - School of life Science, Chongqing University, Chongqing 401331, China.
FAU - Xu, Limei
AU  - Xu L
AD  - Department of Cell Biology, Shandong University School of Medicine, Jinan 250012, 
      China.
FAU - Dong, Ruifen
AU  - Dong R
AD  - Department of Obstetrics and Gynecology, Qilu Hospital, Shandong University, 
      Jinan 250012, China.
FAU - Li, Yinuo
AU  - Li Y
AD  - Department of Obstetrics and Gynecology, Qilu Hospital, Shandong University, 
      Jinan 250012, China.
FAU - Li, Jieyin
AU  - Li J
AD  - Department of Cell Biology, Shandong University School of Medicine, Jinan 250012, 
      China.
FAU - Zhang, Zaixin
AU  - Zhang Z
AD  - Department of Cell Biology, Shandong University School of Medicine, Jinan 250012, 
      China.
FAU - Li, Xiangzhi
AU  - Li X
AD  - Department of Cell Biology, Shandong University School of Medicine, Jinan 250012, 
      China.
FAU - Zhao, Ling
AU  - Zhao L
AD  - Department of Cell Biology, Shandong University School of Medicine, Jinan 250012, 
      China.
FAU - Wei, Jian-Jun
AU  - Wei JJ
AD  - Department of Pathology, Northwestern University School of Medicine, Chicago, IL, 
      USA.
FAU - Shao, Changshun
AU  - Shao C
AUID- ORCID: 0000-0003-2618-9342
AD  - Department of Molecular Medicine and Genetics, Shandong University School of 
      Medicine, Jinan 250012, China.
FAU - Kong, Beihua
AU  - Kong B
AD  - Department of Obstetrics and Gynecology, Qilu Hospital, Shandong University, 
      Jinan 250012, China.
FAU - Liu, Zhaojian
AU  - Liu Z
AD  - Department of Cell Biology, Shandong University School of Medicine, Jinan 250012, 
      China.
LA  - eng
PT  - Journal Article
DEP - 20170811
PL  - England
TA  - Cell Death Differ
JT  - Cell death and differentiation
JID - 9437445
RN  - 0 (MIRN130 microRNA, human)
RN  - 0 (MicroRNAs)
RN  - 0 (NF-kappa B)
RN  - 0 (TSC1 protein, human)
RN  - 0 (Tsc1 protein, mouse)
RN  - 0 (Tuberous Sclerosis Complex 1 Protein)
RN  - 0 (Tumor Suppressor Proteins)
RN  - EC 2.7.1.1 (MTOR protein, human)
RN  - EC 2.7.11.1 (TOR Serine-Threonine Kinases)
SB  - IM
MH  - Animals
MH  - Cystadenocarcinoma, Serous/genetics/*metabolism/pathology
MH  - Female
MH  - HEK293 Cells
MH  - Heterografts
MH  - Humans
MH  - Mice
MH  - Mice, Inbred BALB C
MH  - Mice, Nude
MH  - MicroRNAs/genetics/*metabolism
MH  - NF-kappa B/genetics/*metabolism
MH  - Neoplasm Grading
MH  - Ovarian Neoplasms/genetics/*metabolism/pathology
MH  - Retrospective Studies
MH  - Signal Transduction
MH  - TOR Serine-Threonine Kinases/genetics/*metabolism
MH  - Transfection
MH  - Tuberous Sclerosis Complex 1 Protein
MH  - Tumor Suppressor Proteins/genetics/*metabolism
PMC - PMC5686346
COIS- The authors declare no conflict of interest.
EDAT- 2017/08/12 06:00
MHDA- 2018/07/26 06:00
PMCR- 2018/12/01
CRDT- 2017/08/12 06:00
PHST- 2016/12/04 00:00 [received]
PHST- 2017/06/23 00:00 [revised]
PHST- 2017/07/05 00:00 [accepted]
PHST- 2017/08/12 06:00 [pubmed]
PHST- 2018/07/26 06:00 [medline]
PHST- 2017/08/12 06:00 [entrez]
PHST- 2018/12/01 00:00 [pmc-release]
AID - cdd2017129 [pii]
AID - 10.1038/cdd.2017.129 [doi]
PST - ppublish
SO  - Cell Death Differ. 2017 Dec;24(12):2089-2100. doi: 10.1038/cdd.2017.129. Epub 
      2017 Aug 11.